Alopecia areata
RecruitingA study to evaluate the effectiveness and safety of LAD603 in adults with severe to very severe alopecia areata
- Disease:Alopecia areata
- Substances:–
Bulgaria- Participants:18–64 years
- Sponsor:Almirall S.A.
Rare diseases
Investigational molecules
Locations
Ronda General Mitre 151, 08022 Barcelona, Spain
Research activity is centred on moderate-to-severe atopic dermatitis, with additional interest in nummular dermatitis and broader eczema management in adults and adolescents. The sponsor’s portfolio reflects sustained attention to disease control, symptom relief, and longer-term treatment use in chronic inflammatory skin disease.
These studies focus on persistent cutaneous inflammation and the clinical burden of recurrent pruritus, erythema, and skin barrier dysfunction.
Almirall S.A. runs clinical trials in conditions such as Dermatitis atopic, Hidradenitis, Actinic keratosis, Alopecia areata, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Bulgaria
Bulgaria
Bulgaria
France
Denmark
Germany
Spain
Austria
France
Germany
GermanyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.